MicroRNA-targeting in spermatogenesis: Over-expressions of microRNA-23a/b-3p and its affected targeting of the genes ODF2 and UBQLN3 in spermatozoa of patients with oligoasthenozoospermia by Abu-Halima, Masood et al.
Andrology. 2021;9:1137–1144.  wileyonlinelibrary.com/journal/andr 1137Andrology. 2021;00:1–8.   | 1wileyonlinelibrary.com/journal/andr
Received: 8 January 2021  | Revised: 2 March 2021  | Accepted: 16 March 2021
DOI: 10.1111/andr.13004  
O R I G I N A L  A R T I C L E
MicroRNA- targeting in spermatogenesis: Over- expressions 
of microRNA- 23a/b- 3p and its affected targeting of the 
genes ODF2 and UBQLN3 in spermatozoa of patients with 
oligoasthenozoospermia
Masood Abu- Halima1  |   Anouar Belkacemi2 |   Basim M. Ayesh3 |   Lea Simone Becker1 |   
Amer M. Sindiani4 |   Ulrike Fischer1 |   Mohamad Hammadeh5 |   Andreas Keller6 |   
Eckart Meese1
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
© 2021 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology
Masood Abu- Halima and Anouar Belkacemi Contributed equally to this work. 
1Institute of Human Genetics, Saarland 
University, Homburg, Germany
2Institute of Experimental and Clinical 
Pharmacology and Toxicology, Saarland 
University, Center for Molecular Signaling 
(PZMS), Homburg, Germany
3Department of Laboratory Medical 
Sciences, Alaqsa University, Gaza, 
Palestine
4Department of Obstetrics and 
Gynecology and IVF, Jordan University of 
Science and Technology, Irbid, Jordan
5Department of Obstetrics and 
Gynecology and IVF, Saarland University, 
Homburg, Germany
6Chair for Clinical Bioinformatics, Saarland 
University, Saarbrücken, Germany
Correspondence
Masood Abu- Halima, Institute of Human 




This study was supported by the 
Hedwig Stalter Fund (2016) to Abu- 
Halima M. and Meese E., and protein 
analysis was supported by the Deutsche 
Forschungsgemeinschaft (DFG) CRC 894 
to Belkacemi A
Abstract
Background: Male infertility is a multifactorial syndrome with diverse phenotypic 
representations. MicroRNAs (miRNAs) are small, non- coding RNAs that are involved 
in the post- transcriptional regulation of gene expression. Altered abundance levels 
of ODF2 and UBQLN3 have been reported in patients with different spermatogenic 
impairments. However, the transcriptional regulation of these two genes by miR- 23a/
b- 3p is still unclear.
Objectives: To investigate experimentally whether miR- 23a/b- 3p targets the genes 
ODF2 and UBQLN3 and whether this targeting impacts abundance levels of ODF2 and 
UBQLN3 in patients with oligoasthenozoospermia.
Materials and methods: A total of 92 men attending a fertility clinic were included in 
the study, including 46 oligoasthenozoospermic men and 46 age- matched normozoo-
spermic volunteers who served as controls. Reverse transcription- quantitative PCR 
(RT- qPCR), Western blot, and dual- luciferase (Firefly- Renilla) assays were used to vali-
date the miRNAs and their target genes.
Results: RT- qPCR revealed that miR- 23a/b- 3p was more abundant and ODF2 and 
UBQLN3 targets were less abundant in men with impaired spermatogenesis. Besides, 
Western blot shows that ODF2 and UBQLN3 protein levels were reduced in men with 
impaired spermatogenesis. In silico prediction and dual- luciferase assays revealed that 
potential links exist between the higher abundance level of miR- 23a/b- 3p and the 
lower abundance level of ODF2 and UBQLN3 targets. Mutations in the miR- 23a/b- 
3p- binding site within the 3ˊUTRs (3ˊuntranslated regions) of ODF2 and UBQLN3 
genes resulted in abrogated responsiveness to miR- 23a/b- 3p. Correlation analysis 
showed that sperm count, motility, and morphology were negatively correlated with 
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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1  |  INTRODUC TION
Mal  infertility is a multifactorial pathological condition with diverse 
phenotypic represent ti ns and affects up to 50% of couples’ infer-
tility and accounts for about 20% of total infertility.1 The tiology 
of ale infertility is idiopathic in approximately 40% of the cases, 
even after extensive endocrine, genetic, biochemical, and physical 
examinations.2 Recent transcriptome analysis shows that hundreds 
of genes are expressed exclusively or predominantly in male germ 
cells.3,4 Many of these germ cell- specific genes are thought to 
play a crucial role during spermatogenesis and/or sperm function. 
However, the cellular and biological functions of the ajority of 
these genes are still unclear. Gene expression during spermatogen-
esis is highly dynamic and strictly regulated post- transcriptionally 
via several regulators including microRNAs (miRNAs).5 MiRNAs are 
small, non- coding RNAs that are involved in the post- transcriptional 
regulation of gene expression by inhibiting translation or degrading 
messenger RNA (mRNA).6 To date, 2300 true and validated human 
mature miRNAs have been reported.7 These miRNAs are involved 
in many, if not all, cellular and biological processes investigated, in-
cluding in the spermatogenesis process and during the early stages 
of embryonic development.5,8- 10 Of these miRNAs, miR- 23a and 
miR- 23b demonstrated a dysregulated abundance level in sperma-
tozoa, seminal plasma- derived exosomes, and testicular tissue of 
subfertile men compared to fertile men.11- 15 Recently, increased 
amounts of miR- 23a/b- 3p and reduced amounts of testis- specific 
transcripts were experimentally validated in the spermatozoa and 
testicular tissues of oligoasthenozoospermic men as compared to 
that in normozoospermic men.11 Despite significant advances made 
in miRNA profiling to unravel the regulatory mechanisms underly-
ing complex multifactorial diseases, the exact molecular functions 
of miRNAs have only identified for a very limited number of miR-
NAs involved in fertility disorders. Identifying the functional mRNA 
targets of a particular miRNA can offer a potential therapeutic tar-
get for male infertility or male contraception. According to Human 
Protein Atlas (www.prote inatl as.org), 2237 testis- specific genes 
are showing an elevated expression in testes compared to other 
tissue types. Of these testis- specific genes, two genes, the outer 
dense fiber of sperm tail 2 (ODF2) and the Ubiquilin 3 (UBQLN3) 
were recently identified to be associated with spermatogenesis dis-
orders and male infertility.16- 21 Besides, these genes have binding 
sites for miR- 23a- 3p and miR- 23b- 3p within their 3′UTRs. ODF2 
is expr ssed in the testes, prefer nti lly in round spe mati s.22 It 
encod s a cytoskeleton protei  that is essenti l in sperm cell for-
mation,23 and in protecting the sperm tail from shear forces that 
are trigg red during epididymal transportation and ejaculation.24 
ODF2 also supports the movement of the sperm t il through the 
axon by transmitting power in the flagellum.20 The testis- specific 
gene UBQLN3 is a ubiquitin- like protein expressed exclusively in the 
testes and in elongated spermatids. It is involved in protein process-
ing in the endoplasmic reticulum pathway.25- 27 Although UBQLN3 
is highly expressed in the post- meiotic stage of spermatogenesis, 
and a reduced level was observed in men with non- obstructive azo-
ospermia (NOA),19 Yuan et al, found that Ubqln3 is not necessary 
in the early stages of e bryonic development and spermatogene-
sis.26,27 In this study, we aim to investigate experimentally whether 
miR- 23a/b- 3p targets the genes ODF2 and UBQLN3 and whether 
this targeting impacts expression levels of ODF2 and UBQLN3 in 
men with oligoasthenozoospermia.
2  |  MATERIAL S AND METHODS
2.1  |  Collection and preparation of human sperm 
samples
A total of 92 men were included in the study (mean age ±SD, 
26 ± 4.2 years; range, 18– 35), including 46 oligoasthenozoospermic 
men who attended the IVF center for infertility treatment. Another 
46 age- matched normozoospermic volunteers served as controls. 
The semen samples were newly collected to accomplish the objec-
tive of this study and have not been included in previous studies. 
Semen samples were collected after at least three days of sexual 
abstinence and allowed to liquefy completely for ~30 min at 37°C. 
Basic semen parameters including sperm count (106/mL), motility (% 
motile), and morphology (%) were evaluated according to the World 
Health Organization (WHO) 2010 guidelines. Sperm parameters 
were considered normal when the semen volume was ≥1.5 mL, sperm 
count was ≥15 × 106/mL, total motility was ≥40%, and normal sperm 
morphology was ≥4%. Semen samples from all the participants were 
further purified using Puresperm 45%– 90% discontinuous density 
gradients (Nidacon International) as previously described 14,28 and 
finally transferred to −80°C for long- term storage until total RNA, 
including miRNAs, and protein isolation.
miR- 23a/b- 3p and positively correlated with the lower abundance level of UBQLN3, 
while ODF lower abundance level was positively correlated with sperm motility.
Conclusion: Findings indicate that the higher abundance level of miR- 23a/b- 3p and 
the lower abundance level of ODF2 and UBQLN3 targets are associated with oligoas-
thenozoospermia and male subfertility.
K E Y W O R D S
male subfertility, Oligoasthenozoospermia, ODF2, UBQLN3, and miR- 23a/b- 3p
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
    |  3- I  et AL.
2.2  |  Sperm RNA isolation
For RNA including miRNA isolation, sperm samples stored at −80°C 
were thawed on ice and washed three times with phosphate- 
buffered saline (PBS). Spermatozoa were mixed with 700 µL QIAzol 
Lysis Reagent (Qiagen), supplemented with dithiothreitol (DTT) 
(80 mM; Sigma- Aldrich), and allowed to completely lyse for 2 h at 
room temperature (RT). Subsequently, the procedure was completed 
according to the manufacturer's instructions for Qiagen miRNeasy 
Mini Kit using QIAcube™ Robotic Workstation. The quantity and 
quality of RNA were assessed using the NanoDrop spectrophotom-
eter (Thermo Fisher Scientific). A DNase I treatment step was in-
cluded during the isolation procedure to remove any contaminating 
DNA using the RNase- free DNase Set (Qiagen).
2.3  |  Reverse transcription and quantitative real- 
time PCR
Complementary DNA (cDNA) was generated in 20 µL reactions by 
reverse transcription (RT) of 100 ng RNA using the miScript RT II 
Kit (Qiagen) according to the manufacturer's instructions. The 5x 
miScript HiFlex buffer was used to prepare cDNA from total RNA 
including miRNAs and mRNAs. The resulting cDNA was then diluted 
to 0.5 and 2.5 ng/μL for the determination of miRNA and mRNA 
abundance levels, respectively. The cDNA was then amplified by the 
miScript SYBR Green PCR Master Mix (Qiagen), for quantification of 
miR- 23a- 3p and miR- 23b- 3p and their functionally validated target 
genes, that is, ODF2 and UBQLN3. All RT- qPCR experiments were 
performed using the Liquid Handling Robot QIAgility™ (Qiagen) be-
fore performing RT- qPCR using the StepOnePlus™ Real- Time PCR 
system (Applied Biosystems). As reference endogenous controls, 
the GAPDH was used for mRNA normalization, and the combination 
of RNU6B, miR- 100- 5p, and miR- 30a- 5p for miRNA normalization as 
previously recommended 11,14,15,28,29 because of their minimum vari-
ance between samples as observed by the DataAssist™ Software 
(Applied Biosystems). Moreover, no template controls (NTC) and 
RT negative controls were included. A miRNA RT control (miRTC) 
was performed to assess the performance of the RT reactions. The 
miScript and exon- spanning QuantiTect primer assays (Qiagen) were 
purchased from Qiagen.
2.4  |  Prediction of miR- 23a/b- 3p target genes
We performed an in silico analysis to identify the predicted target 
genes for miR- 23a/b- 3p, that is, hsa- miR- 23a (MIMAT0000078) and 
hsa- miR- 23b (MIMAT0000418) using miRWalk 2.0.30 By including 
only the potential target genes which have been detected by at 
least 4 out of the 12 algorithms integrated in miRWalk, ~13,000 po-
tential target genes were predicted. The cross- match between the 
predicted genes and the testis- specific genes that showed a higher 
abundance level in testes compared to other tissue types according 
to Human Protein Atlas (2237 genes) yielded 1097 targets that were 
further investigated for a functional role in spermatogenesis and/or 
sperm function. The ODF2 and UBQLN3 target genes were selected 
for further validation experiments. These two genes have binding 
sites for miR- 23a- 3p and miR- 23b- 3p in their 3ˊUTR and are also 
known to be involved in sp rmatogenesis and/or sperm function
2.5  |  Cell line, cell culture, and plasm d constructs
The human mbryonic kidney c ll line (HEK- 293 T) was used for the 
dual- luciferase (Firefly- Renilla) assays. HEK- 293 T cells were main-
tain d in Dulbecco's modified Eagle's m dium (DMEM, Thermo 
Fisher Scientific) suppleme ted with 10% fetal bovine serum 
(Biochrom), 100 U/mL p nicillin, an  100 µg/mL streptomycin 
(Sigma- Aldrich). HEK- 293 T cells wer  incubate  at 37°C in a humidi-
fied 5% CO2 at osphere and subcultured following trypsinization 
with a 1x solution of 0.05% trypsin- EDTA (Thermo Fisher Scientific). 
The over- expression of miR- 23a- 3p and miR- 23b- 3p was confirmed 
by Northern blot in HEK- 293 T cells as previously observed. 11 Both 
the reporter plasmid (pMIR- RNL- TK) and the expression plasmid 
(pSG5) harbor the SV40 promotor. The pSG5- miR- 23a and pSG5- 
miR- 23b were constructed by cloning the miR- 23a- 3p/5p and miR- 
23b- 3p/5p precursors downstream to the T7 viral promoter in the 
pSG5 expression vector (Agilent Technologies). The 3ˊUTRs of 
ODF2 and UBQLN3 potential target genes were cloned in the pMIR- 
RNL- TK dual- luciferase reporter vector (Thermo Fisher Scientific), 
downstream to the luciferase gene as previously described.11 These 
constructs served to determine the ability of miR- 23a- 3p and miR- 
23b- 3p to suppress the luciferase expression when bound to their 
corresponding site in the 3ˊUTR. Plasmids containing the wild- type 
3′UTR are designated with the suffix - WT, and those containing the 
3′UTR with mutated miR- 23 binding sites are designated the suffix 
- Mut. Specific primer sequences and restriction sites are listed in 
Table S1 and the size, reference, and location of the cloned frag-
ments are listed in Table S2.
2.6  |  Transfection and dual- luciferase 
activity assay
For dual- luciferase assays, 1 × 105 HEK- 293 T cells were seeded 
in 24- well culture plates. After 24 h, cells in each well were si-
multaneously transfected with 0.2 µg of the corresponding re-
porter gene construct (pMIR- ODF2 or pMIR- UBQLN3) and 0.8 µg 
of the expression vector (pSG5- miR- 23a or pSG5- miR- 23b). 
Transfections were performed using a 2 µL PolyFect transfection 
reagent (Qiagen) according to the manufacturer's recommenda-
tions. Empty pMIR- RNLTK and empty pSG5 vectors were included 
in every single treatment as controls. Two days post- transfection, 
cells were harvested and assayed using the dual- luciferase assay 
system (Promega) as recommended by the manufacturer. Each 
treatment was performed in duplicate, in three independent 
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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experime ts. The results were expr ss d as mean relative l cif-
erase activity ±SE (Firefly luciferas  light units/Renilla lucif rase 
light units). The experiments were carried out in seven and four 
independent biol gical replicates for th  wild and mutant types, 
respectively, each in duplicates.
2.7  |  Protein lysat  reparation and western blot
Frozen human sperm samples were thawed on ice and washed four 
times with phosphate- buffered saline (PBS, containing 137 mM 
NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, and pH 
7.4) by centrifugation at 10,000 × g at 4°C for 5 in. The pellet was 
resuspended in RIPA buffer containing (150 mM NaCl, 50 mM Tris, 
5 mM EDTA, % Nonidet P- 40, 0.1% SDS, 0.5% Na- deoxycholate, 
and pH 7.4) supplemented with complete protease inhibitor cock-
tail and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche). 
The resulting sperm suspension was sonicated on ice for 2 s, in-
cubated at 4°C for 30 min under rotation, and then centrifuged at 
16,900 × g at 4°C for 15 min. The supernatant was collected, and 
the concentration of solubilized protein was determined using the 
bicinchoninic acid assay (BCA assay) (Thermo Fisher Scientific) 
according to the manufacturer's protocol. Proteins were dena-
tured in SDS- denaturing buffer containing (4% (w/v) SDS, 60 mM 
Tris, 0.005% (w/v) bromophenol blue, 10% (v/v) glycerol, 5% (v/v) 
2- mercaptoethanol, and pH 6.8 at 60°C for 1 h. Western blot was 
performed as previously described. 31 Proteins (50 µg per lane) 
were separated by SDS- PAGE 4%– 20% Mini- Protean TGX gels (Bio- 
Rad Laboratories) and transferred to a Nitrocellulose membrane 
(0.2 µm; Bio- Rad Laboratories). The unoccupied membrane binding 
sites were blocked by incubation in TBS buffer (containing in mM 
150 NaCl, 10 Tris- HCl, and pH 8.0) supplemented with 5% (w/v) dry 
milk powder at 21°C for 1 h. The membrane was probed with rabbit 
polyclonal antibodies against ODF2 (1:1000; Bethyl Laboratories, 
Cat. Nr. A303- 546A), Ubiquilin 3 (1:1000; Thermo Fisher Scientific, 
Cat. Nr. PA5- 12080) or β- Actin (1:1000, Abcam, Cambridge, UK, Cat 
Nr. ab8227) overnight at 4°C under gentle shaking. After washing 
with TBS, the membrane was incubated with the respective sec-
ondary antibodies conjugated to the horseradish peroxidase to de-
tect primary antibodies after the addition of the Western Lightning 
Chemiluminescence Reagent Plus (PerkinElmer, Waltham, MA, USA) 
using the LAS- 3000 analyzer (Fujifilm). Thereafter, membranes 
were stripped of bound antibodies and reprobed with anti- β- Actin 
(1:1000, Abcam, Cat Nr. ab8227) as a loading control.
2.8  |  Statistical analysis
GraphPad Prism Software version 7 (GraphPa  Software) was 
used for statistical analysis. Data were presented as mean ±SD or 
SEM as indicated in each paragraph. A priori power analysis with 
α and β error probability of 0.05 was lied to determin  the 
sample size for ach gr up, showing that ≥27 samples per group 
are required. U paired two- tailed t- test was used to evaluate the 
differences in miRNA and mRNA abundance levels between sub-
fertile and controls. The relative quantitative method of 2– ∆∆Ct 
was used to measure the dynamic change of miRNA and mRNA 
abundance levels32 Spearman correlation analysis was per-
formed in GraphPad Prism to find the association between basic 
semen parameters and the abundance levels of ODF2, UBQLN3, 
miR- 23a- 3p, and miR- 23b- 3p. p < 0.05 was considered statisti-
cally significant. Western blot images were saved as TIFF files 
and transferred to Coral DRAW X7 version 17.0 for clarity and 
labeling.
3  |  RESULTS
3.1  |  Basic parameters of oligoasthenozoospermic 
men and normozoospermic controls
The characteristics of the spermiogram of the oligoasthenozoosper-
mic (n = 46) and age- matched normozoospermic volunteers (n = 46) 
are shown in Table 1. Subfertile men with oligoasthenozoospermia 
were significantly different compared to normozoospermic men in 
terms of sperm count, motility, and morphology (p <0.05). Other 
parameters, such as age, volume, pH, and viscosity, were not signifi-
cantly different.
3.2  |  Abundance level of miR- 23a- 3p and miR- 23b- 
3p in the spermatozoa
The abundance level of miR- 23a- 3p and miR- 23b- 3p was deter-
mined in 43 men with oligoasthenozoospermia compared with 43 
normozoospermic volunteers using RT- qPCR analysis. As shown 
in Figure 1A, the abundance levels of miR- 23a- 3p and miR- 23b- 3p 
were significantly higher in oligoasthenozoospermic men compared 
to that in age- matched normozoospermic men (2.06 and 1.91 folds 
respectively, p < 0.0001).
Parameters
Oligoasthenozoospermic
men (n = 46)
Normozoospermic
men (n = 46) p- value
Count (106/mL) 9.40 ± 2.32 69.09 ± 15.02 <0.0001
Motility (% motile) 20.21 ± 4.84 59.33 ± 11.52 <0.0001
Morphology (%) 14.98 ± 3.94 22.26 ± 3.72 <0.0001
Note: Unpaired two- tailed t- test. Data were presented as mean ±standard deviation. P < 0.05 was 
considered statistically significant.
TA B L E  1  Semen characteristics
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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3.3  |  Abundance level of ODF2 and UBQLN3 in the 
spermatozoa
The abundance levels of ODF2 and UBQLN3 genes were analyzed by 
RT- qPCR using the same sperm samples from men with oligoasthe-
nozoospermia and age- matched controls. Compared with normozo-
ospermic men, significantly reduced abundance levels of ODF2 and 
UBQLN3 were observed in oligoasthenozoospermic men compared 
with that in age- matched normozoospermic men (2.09- and 3.83- fold, 
respectively, p < 0.0001) (Figure 1B). In line with the RT- qPCR gene 
expression analysis, we performed Western blot experiments to look 
for the ODF2 and Ubiquilin 3 protein levels in sperm sampl s from 
normozoospermic an  oligoasthenozoospermic men. I  agreement 
with the RT- qPCR d ta, sperm samples from oligoasthenozoosp r-
mic m n show a reduced level of ODF2 and Ubiquilin 3 protein levels 
compared with the control normozoospermic men (Figure 2A and B).
3.4  |  Correl tion of miR- 23a/b- 3p, ODF2, and 
UBQLN3 abundance levels (∆Ct) t  semen parameters
To s udy whether there were correlations between the miR- 
23a/b- 3p, ODF2, and UBQLN3 and the b sic semen parameters, 
Spearman correlation an lyses betwe n the abundance levels (∆Ct) 
of miR- 23a/b- 3p, ODF2, and UBQLN3 and ba ic semen parameters 
were tested. As summarized in Table S3, the hig r the abund nce 
levels of miR- 23a- 3p and miR- 23b- 3p (i.e., lower ∆Ct), the lower the 
sp rm count, motility, and the number of cells exhibiting normal 
orphol gy (p < 0.0001). Furthermore, we analyzed the correla-
tion betwee  the abundance level of ODF2 and UBQLN3 and basic 
sperm parameters. The results significantly demonstrated that the 
ODF2 abundance level was positively correlated with sperm motil-
ity (p = 0.011), while UBQLN3 was correlated positively with sperm 
count, motility, and the number of cells exhibiting normal morphol-
ogy (p < 0.001) (Table S3).
3.5  |  Target gene validation by dual- 
luciferase assay
The binding of miR- 23a- 3p and miR- 23b- 3p on the 3′UTR of ODF2 
and UBQLN3 target genes was validated using the dual- luciferase 
assay. Figure 3A and B show the location of the predicted binding 
sites of miR- 23a- 3p and miR- 23b- 3p in the 3′UTRs of ODF2 and 
UBQLN3. Co- transfection of HEK- 293 T cells with pMIR- ODF2- 
3′UTR- WT or pMIR- UBQLN3- 3′UTR- WT plasmids together with 
plasmids expressing the corresponding miRNA leads to a reduction 
F I G U R E  1  Abundance levels of (A) miR- 23a/b- 3p and (B) ODF2 and UBQLN3 in the spermatozoa from oligoasthenozoospermic 
men (n = 43) and age- matched normozoospermic men (n = 43) as determined by RT- qPCR. Data are presented as the mean ∆Ct of 
oligoasthenozoospermic and normozoospermic men (lower ∆Ct, higher abundance level). The p- value was calculated using unpaired two- 
tailed Student's t- test and p < 0.05 was considered statistically significant (*p < 0.05; **p < 0.001; and ***p < 0.0001)
F I G U R E  2  Western blot of protein lysates (50 µg per lane) 
isolated from spermatozoa of normozoospermic (normo.) or 
oligoasthenozoospermic (oligoastheno.) donors. Western blots 
were probed with antibodies against the (A) outer dense fiber of 
sperm tail 2 (ODF2) (95.4 kDa), (B) Ubiquilin 3 (70.8 kDa), and the 
β- actin (41.7 kDa) as a loading control
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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of the luciferase activity (Figure 3C and D). A significant reduction 
in luciferase activity was observed when pMIR- ODF2- 3′UTR- WT 
with plasmid bearing miR- 23a- 3p- binding site (reductions 22.93%, 
p < 0.0001) and miR- 23b- 3p (27.27%, p < 0.0001) (Figure 3C). 
Similarly, the co- transfection of miR- 23a- 3p and miR- 2 b- 3p with 
the pMIR- UBQLN3- 3′UTR- WT reporter plasmid showed a reduc-
tion of the luciferase activity by 31.63% (p < 0.0001) and 23.02% 
(p < 0.0001), respectively (Figure 3D). In the meanwhile, no signifi-
cant reduction was observed in the case of co- transfection of an 
empty control vector (pMIR- RNL- TK), or vectors bearing an inten-
tionally mutated miR- 23a- 3p- and miR- 23b- 3p- binding sites (pMIR- 
ODF2- 3′UTR- Mut and pMIR- UBQLN3- 3′UTR- Mut) (Figure 3A 
and B). Collectively, these results provided supporting functional 
evidence that miR- 23a- 3p and miR- 23b- 3p bind to the 3′UTR of 
ODF2 and UBQLN3, resulting in a reduction of the luciferase signal 
activity.
4  | DISCUSSION
In this study, the higher the abundance level of miR- 23a/b- 3p and the 
lower the abundance level of ODF2 and UBQLN3 target genes were 
confirmed by RT- qPCR and Western blot, respectively, in sperm 
samples of 46 oligoasthenozoospermic men and 46 age- matched 
normozoospermic men. The abundance level of miR- 23a/b- 3p 
was negatively and UBQLN3 was positively correlated with sperm 
count, motility, and the number of cells exhibiting normal morphol-
ogy, while ODF2 was positively correlated with sperm motility. The 
over- expression of miR- 23a- 3p and miR- 23b- 3p was confirmed by 
Northern blot in HEK- 293 T cells, as we previously described,11 in-
dicating that these two miRNAs (i.e., miR- 23a- 3p and miR- 23b- 3p) 
are actual miRNAs. A significant decrease in the luciferase activity 
for ODF2 and UBQLN3 targets was observed, suggesting a post- 
transcriptional regulation by miR- 23a/b- 3p.
F I G U R E  3  Schematic diagram of the reporter gene vectors including miR- 23a/b- 3p- binding sites and dual- luciferase reporter gene of the 
3′UTRs of ODF2 and UBQLN3. (A) ODF2- 3′UTR and (B) UBQLN3- 3ˊUTR, the location of the predicted binding sites of miR- 23a- 3p and miR- 
23b- 3p in the 3ˊUTRs of ODF2 and UBQLN3, the sequences of the binding sites of miR- 23a- 3p and miR- 23b- 3p, and the mutated binding 
sites (underlined bold letters) are shown. (C) ODF2- 3ˊUTR and (D) UBQLN3- 3ˊUTR, HEK 293 T cells wer  tra sfected with empty vectors, 
reporter gene c n tructs, and miRNA- expression plasmids in the indicated combinations. The luciferase activity of the control vector 
experiment was set to 100%. The results represent the mean of seven and four independent biological replicates for the wild and mutant 
types, respectively, each in duplicates. Data are presented as mean ±standard deviation, and the p- value was calculated using unpaired two- 
tailed Student's t- test (*p < 0.05, **p < 0.001, and ***p < 0.0001)
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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Studies have revealed that the abundance level of ODF2 and 
UNQNL3 targets was decreased, both at mRNA and protein levels, 
in sperm and testicular tissue samples by microarray, RT- qPCR, 
and Western blot.16- 21 Specifically, in the sperm samples of men 
with asthenozoospermia, the abundance level of ODF2 was re-
duced compared with that in men with normozoospermia 17 and 
this reduction in the abundance level might result in the aberration 
of the outer dense fibers (ODFs) that are surrounded the axoneme 
of the sperm tail and preserve the elastic rigidity of sperm fla-
gellum,33 resulting in reduced sperm motility. Zhao et al showed 
that asthenozoospermia is associated with aberrant ODF struc-
tures and that a conditional knockout of ODF2 in mice leads to 
asthenozoospermia phenotype.21 Besides, he also found a higher 
percentage of ODF defects in the sperm samples of men with as-
thenozoospermia as compared to that in normozoospermic men 
and the percentage of defects was significantly correlated with the 
percentage of axoneme defects and non- motile spermatozoa, as 
determined by transmission electron microscopy analysis.21 Using 
Western blot analysis, the expression levels of ODF major compo-
nents (ODF1, ODF2, ODF3, and ODF4) were also down- regulated 
in asthenozoospermic men as compared to that in normozoosper-
mic men.21 Altogether, these findings indicate that ODF2 plays an 
essential role in protecting the sperm tail from shear forces and 
supports the movement of the sperm tail and its loss of function 
may represent an initiating event underlying male factor subfer-
tility, specifically, asthenozoospermia. In concordance with these 
findings, our results show that the abundance level of ODF2 was 
lower in the sperm samples of oligoasthenozoospermic men, as 
compared to that in normozoospermic men. Moreover, the lower 
abundance level was positively correlated with reduced sperm 
motility, providing good evidence of using ODF2 as a biomarker 
for sperm dysfunction, specifically, for sperm motility.
Similarly, a significantly reduced abundance level of UBQLN3 was 
observed in the testicular tissue of subfertile men with various types 
of NOA and controls by using microarrays.19 In that study, the re-
duced abundance level was positively correlated with the degree of 
spermatogenic impairment.19 Although UBQLN3 is highly expressed 
in the post- meiotic stage of spermatogenesis, in elongated sperma-
tids, Yuan et al, found that Ubqln3 is unnecessary for embryonic 
development and spermatogenesis in mice.26,27 However, the abun-
dance level of UBQLN3 in male subfertility remains highly unclear. In 
agreement with our results, a reduced abundance level of UBQLN3 
was observed in the sperm samples of oligoasthenozoospermic men, 
when compared with the controls. It is legitimate to hypothesize that 
the altered abundance level of the UBQLN3 in sperm mirrors to a 
high extend the UBQLN3 expression pattern in testes, where the 
UBQLN3 is highly expressed, and its altered lower expression may 
adversely affect the spermatogenic process and subsequently may 
result in the development of male subfertility. Based on our litera-
ture analysis, there is no study endeavored to ascertain the expres-
sion level of UBQLN3, at mRNA and/or protein levels using a reliable 
and robust method like RT- qPCR and/or Western blot in the sperma-
tozoa and fresh testicular tissues from men with subfertility.
In this study, a higher abundance level of miR- 23a/b- 3p was vali-
dated to cause a lower abundance of ODF2 and UBQLN3 by RT- qPCR 
using the ame sperm samples from m n with oligoasthenozoosper-
mia and age- matched controls. Furtherm re, these results were fur-
ther c nfirmed by Western blot showing reduced ODF2 and Ubiquilin 
3 protein levels n sperm samples from men with oligoasthenozo-
ospermia. It is thus conc ivable that the binding of miR- 23a/b- 3p on 
he 3ˊUTR of ODF2 and UBQLN3 lower t e abundance level of these 
two targets so that the phenotyp  of subfertility is bserved.
5  |  CONCLUSION
Our findings confirm our observation of the inverse correlation be-
tween the higher abundance level of miR- 23a/b- 3p and the lower 
abundance l vel of ODF2 and UBQLN3. The observed inv rse cor-
relation levels of these two genes are likely coordinated by miR- 
23a/b- 3p and that increased abundance level of miR- 23a/b- 3p may 
have the potential in affecting spermatogenetic activity adversely, 
probably through influencing the sperm count, motility, and mor-
phology. It is important to note that the major limitation in our work 
was the lack of fresh testicular biopsies. The shortcoming pre-
vented us from identifying the abundance level of these two miR-
NAs and genes in the testes, where the spermatogenesis process 
takes place. Therefore, our findings need to be further confirmed 
in testicular tissue samples to further define and understand the 
relationship between the inverse correlation of miR- 23a/b- 3p and 
ODF2 and UBQLN3 and male subfertility development.
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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